neo-Isopulegol is one of the isopulegol-family monoterpene alcohol isomers found in citronellal-rich materials such as lemon eucalyptus oil. The clearest evidence supports its identity, its repeated occurrence in Corymbia citriodora compositions, and its contribution to the woody-herbal side of that aroma profile. A smaller preclinical literature suggests sedative-style central nervous system effects for neo-isopulegol-containing monoterpene testing, but direct constituent-specific safety and human data remain limited.
Aroma and practical use
- Use the recorded herbal, minty, licorice-like, woody, herbaceous descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Compare the recorded goal signals with the intended purpose, while keeping model assumptions separate from observed study outcomes.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
The China Corymbia citriodora oil paper reported citronellal at 76.3%, citronellol at 5.7%, and neo-isopulegol at 5.5%, placing neo-isopulegol among the oil's three major constituents.
The China Corymbia citriodora oil paper reported citronellal at 76.3%, citronellol at 5.7%, and neo-isopulegol at 5.5%, placing neo-isopulegol among the oil's three major constituents.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
The same study linked the fresh citrus character mainly to citronellal and citronellol, while assigning woody side notes to neo-isopulegol.
The same study linked the fresh citrus character mainly to citronellal and citronellol, while assigning woody side notes to neo-isopulegol.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2007 mouse study reported that isopulegol and neo-isopulegol showed depressant effects in the pentobarbital-induced sleep test, indicating sedative-like activity in that preclinical model.
A 2007 mouse study reported that isopulegol and neo-isopulegol showed depressant effects in the pentobarbital-induced sleep test, indicating sedative-like activity in that preclinical model.
This experimental finding does not establish benefit, dose or safety in people using this blend.
How it contributes to goal calculations
Model markers guide the formulation score. They are separate from the source findings above.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedNo dedicated neo-isopulegol fragrance safety monograph or constituent-specific dermal maximum was verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Because most accessible evidence is identity, occurrence, and preclinical behavioral testing, consumer-facing copy should avoid medical or nervous-system benefit claims.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
Depressant or sedative-like central nervous system effects were observed in pentobarbital-induced sleep testing.
The accessible evidence is preclinical and behavioral rather than a fully mapped receptor-level mechanism specific to neo-isopulegol.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- Direct human data for isolated neo-isopulegol were not verified.
- Dedicated constituent-specific dermal, inhalation, and sensitization evidence remains sparse.
- Most accessible bioactivity evidence is preclinical and should not be translated into therapeutic copy.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.